inv(16)(p13q24) CBFA2T3/GLIS2
2012-11-01 Jean-Loup Huret   Affiliation1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France
Clinics and Pathology
Disease
Note
Acute megakaryoblastic leukemia (AMKL) was so far divided into three subgroups: AMKL arising in patients with Down syndrome (DS-AMKL), AMKL with a t(1;22)(p13;q13) giving rise of a 5 OTT - 3 MAL fusion gene, and "other" AMLKs, i.e. non Down syndrome / non t(1;22).
Two new categories have recently been individualized from the subgroup "non Down syndrome / non t(1;22)": the inv(16)(p13q24) CBFA2T3/GLIS2, and the t(11;12)(p15;p13) NUP98/KDM5A (Gruber et al., 2012; Thiollier et al., 2012).
Two new categories have recently been individualized from the subgroup "non Down syndrome / non t(1;22)": the inv(16)(p13q24) CBFA2T3/GLIS2, and the t(11;12)(p15;p13) NUP98/KDM5A (Gruber et al., 2012; Thiollier et al., 2012).
Epidemiology
Fourteen patients with data on sex and age are available; median age at diagnosis was 1 year - 1 year 4 months (range 6 months - 4 years 7 months).
The inv(16)(p13q24) CBFA2T3/GLIS2 was found in about 30% of non-Down syndrome pediatric AMKL cases (in 13 of 48 cases in Gruber et al., 2012, and 7 of 22 cases in Thiollier et al., 2012. So far, none of the 36 adult AMKL cases under study contained the chimeric transcript.
One patient had a Down syndrome (case SJAMLM7018 in Gruber et al., 2012), which shows that DS-AMKL and inv(16)-AMLK categories are not mutually exclusive.
The inv(16)(p13q24) CBFA2T3/GLIS2 was found in about 30% of non-Down syndrome pediatric AMKL cases (in 13 of 48 cases in Gruber et al., 2012, and 7 of 22 cases in Thiollier et al., 2012. So far, none of the 36 adult AMKL cases under study contained the chimeric transcript.
One patient had a Down syndrome (case SJAMLM7018 in Gruber et al., 2012), which shows that DS-AMKL and inv(16)-AMLK categories are not mutually exclusive.
Prognosis
Subgroup of patients with a significantly worse overall survival at 5 years as compared to patients with AMKL that lacked this chimeric transcript (28% versus 42% in Gruber et al., 2012); fusion associated with treatment-refractory disease (Thiollier et al., 2012).
Genes Involved and Proteins
Gene name
GLIS2 (GLIS family zinc finger 2)
Location
16p13.3
Protein description
Kruppel-like zinc-finger protein. Transcription factor; repressor of the Hedgehog signaling pathway; repressor of the Wnt signaling pathway. GLIS2 has also been reported to localize to the primary cilium. A mutation GLIS2 has been linked to the development of nephronophthisis. Glis2 may act as a repressor of epithelial-mesenchymal transition (EMT) and EMT-related gene expression (Lichti-Kaiser et al., 2012).
Gene name
CBFA2T3 (core-binding factor, runt domain, alpha subunit 2; translocated to, 3)
Location
16q24.3
Result of the Chromosomal Anomaly
Description
5 CBFA2T3 - 3 GLIS2. Fusion between exon 10 of CBFA2T3 and exon 3 of GLIS2 in 6 cases (Gruber et al., 2012); fusion between exon 11 of CBFA2T3 and exon 3 of GLIS2 in 1 case (Thiollier et al., 2012); fusion between exon 11 of CBFA2T3 and exon 1 of GLIS2 in 1 case (Gruber et al., 2012).Retains the three CBFA2T3 N-terminal nervy homology regions (NHR) that mediate protein interactions and the five GLIS2 C-terminal domains (ZnF) responsible for interaction with DNA and transactivation. The MYND (myeloid, nervy, and Deaf-1 domain, class of zinc finger domain reported to interact with the N-CoR repressor complex) domain of CBFA2T3 is lost.
Oncogenesis
This fusion between two transcriptional regulators results in aberrant expression of genes controlled either by CBFA2T3 or GLIS2 (Thiollier et al., 2012).
There is an homogenous gene expression signature including a strong expression of CD56. Among the differentially regulated genes are known targets of the Hedgehog pathway including BMP2, BMP4, GATA3, and CCND2. CBFA2T3/GLIS2 induces BMP signaling. Hedgehog and JAK-STAT pathways are significantly upregulated (Gruber et al., 2012; Thiollier et al., 2012). CBFA2T3/GLIS2 cells demonstrated enhanced self-renewal in vitro (Gruber et al., 2012). Aurora A kinase (AURKA) inhibitors can induce differentiation and inhibits proliferation of AMKL blasts (Thiollier et al., 2012).
There is an homogenous gene expression signature including a strong expression of CD56. Among the differentially regulated genes are known targets of the Hedgehog pathway including BMP2, BMP4, GATA3, and CCND2. CBFA2T3/GLIS2 induces BMP signaling. Hedgehog and JAK-STAT pathways are significantly upregulated (Gruber et al., 2012; Thiollier et al., 2012). CBFA2T3/GLIS2 cells demonstrated enhanced self-renewal in vitro (Gruber et al., 2012). Aurora A kinase (AURKA) inhibitors can induce differentiation and inhibits proliferation of AMKL blasts (Thiollier et al., 2012).
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 40866546 | 2025 | A stem cell differentiation model reveals two alternative fates in CBFA2T3::GLIS2-driven acute megakaryoblastic leukemia initiation. | 130 |
| 39808803 | 2025 | Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements. | 113 |
| 33439382 | 2021 | Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy. | 101 |
| 26186939 | 2015 | The biology of pediatric acute megakaryoblastic leukemia. | 98 |
| 43004022 | 2026 | Advances in CBFA2T3::GLIS2 fusion gene in pediatric acute myeloid leukemia: from molecular mechanisms to targeted therapeutic strategies. | 89 |
| 39781610 | 2025 | Novel classification system and high-risk categories of pediatric acute myeloid leukemia. | 76 |
| 41507381 | 2026 | Identifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia. | 76 |
| 37019972 | 2023 | Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication. | 71 |
| 40565358 | 2025 | Extramedullary Relapse of CBFA2T3::GLIS2-Positive Megakaryoblastic Leukemia Mimicking Secondary Ewing Sarcoma: An Exemplary Case for the Diagnostic Trap. | 71 |
| 38798454 | 2025 | EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML. | 70 |
| 37729615 | 2024 | CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216. | 69 |
| 23153540 | 2012 | An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. | 69 |
| 40470252 | 2025 | Identifying Targeted Therapies for CBFA2T3::GLIS2 Acute Myeloid Leukemia. | 65 |
| 39384814 | 2024 | CBFA2T3-GLIS2 mediates transcriptional regulation of developmental pathways through a gene regulatory network. | 56 |
| 41141393 | 2026 | Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2-driven pediatric acute megakaryoblastic leukemia. | 52 |
| 36789545 | 2023 | Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group. | 51 |
| 31719049 | 2020 | Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. | 50 |
| 38086945 | 2024 | Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia. | 49 |
| 24127550 | 2013 | DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. | 48 |
| 23045605 | 2012 | Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. | 48 |
| 28174417 | 2017 | AMKL chimeric transcription factors are potent inducers of leukemia. | 45 |
| 30592296 | 2019 | CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. | 44 |
| 36136600 | 2022 | CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. | 42 |
| 41348020 | 2025 | Using genomics to refine pediatric AML risk stratification. | 41 |
| 28112737 | 2017 | Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. | 41 |
| 27114462 | 2016 | Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study. | 39 |
| 39866946 | 2025 | Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56-positive acute leukemias. | 35 |
| 38786053 | 2024 | CBFA2T3 Is PPARA Sensitive and Attenuates Fasting-Induced Lipid Accumulation in Mouse Liver. | 34 |
| 33811445 | 2021 | CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript. | 27 |
| 41991315 | 2026 | [Acute megakaryoblastic leukemia with CBFA2T3::GLIS2 fusion gene: 3 cases report and literature review]. | 27 |
| 38315896 | 2024 | Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene. | 26 |
| 42926483 | 2026 | CBFA2T3-GLIS2 establishes transcriptionally permissive enhancer hypermethylation associated with venetoclax response in pediatric AML. | 25 |
| 35294081 | 2022 | Acute megakaryoblastic leukemia with trisomy 3 and CBFA2T3::GLIS2: A case report. | 24 |
| 33832921 | 2021 | Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies. | 24 |
| 42255261 | 2026 | Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia. | 22 |
| 36003795 | 2022 | Revealing the intratumoral heterogeneity of non-DS acute megakaryoblastic leukemia in single-cell resolution. | 22 |
| 42824020 | 2026 | Case Report: CBFA2T3::GLIS2-positive myeloid sarcoma with focal bone marrow involvement mimicking Ewing sarcoma in an infant. | 20 |
| 27094503 | 2016 | Clinical Courses of Two Pediatric Patients with Acute Megakaryoblastic Leukemia Harboring the CBFA2T3-GLIS2 Fusion Gene. | 18 |
| 37601875 | 2023 | CBFA2T3::GLIS2-positive acute leukemia with RAM and mixed T/megakaryocytic phenotype. | 16 |
| 35927023 | 2022 | Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy. | 14 |
| 41960216 | 2026 | Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing. | 13 |
| 31294507 | 2020 | Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. | 12 |
| 28109323 | 2017 | Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene. | 10 |
| 34976721 | 2022 | Acute myeloid leukemia with RAM immunophenotype presenting with extensive mesenteric and retroperitoneal lymphadenopathy: A case report and review of the literature. | 8 |
| 37716355 | 2023 | CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax. | 0 |
| 39145456 | 2024 | CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. | 0 |
| 31792123 | 2019 | Oncogenic Drivers and Development. | 0 |
| 38639201 | 2024 | Immunophenotypic clustering in paediatric acute myeloid leukaemia. | 0 |
| 41058336 | 2026 | BH3 mimetic therapies for CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia. | 0 |
| 36346368 | 2023 | Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression. | 0 |
| 37078511 | 2023 | Acute myeloid leukemia with RAM immunophenotype: A new underdiagnosed entity. | 0 |
| 30842387 | 2019 | [Prognostic significance of chimeric fusion gene analysis in pediatric acute megakaryoblastic leukemia]. | 0 |
| 37548333 | 2023 | BCR-ABL1 co-occurring with CBFA2T3-GLIS2 and RAM immunophenotype in a non-Down syndrome infant with acute megakaryoblastic leukemia. | 0 |
| 28063190 | 2017 | Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome. | 0 |
| 40931630 | 2025 | A Case of Blinatumomab Efficacy in RAM Immunophenotype/CBFA2T3::GLIS2 Fusion AML. | 0 |
| 37693371 | 2023 | Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy. | 0 |
| 39976431 | 2025 | A Rare Case of Acute Leukemia With CBFA2T3::GLIS2 Fusion Exhibiting a T/Megakaryocyte Mixed Phenotype. | 0 |
| 31092368 | 2019 | The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children. | 0 |
| 31612466 | 2020 | Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup. | 0 |
| 31736254 | 2020 | CBFA2T3-GLIS2-positive acute megakaryoblastic leukemia in a patient with Down syndrome. | 0 |
| 23407549 | 2013 | CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. | 0 |
| 30305534 | 2018 | [Genetic aberrations and new treatment strategies for pediatric acute myeloid leukemia]. | 0 |
| 42500906 | 2026 | Rapid Molecular Diagnostics Enables Individualized Frontline Treatment of CBFA2T3::GLIS2-Rearranged Acute Myeloid Leukemia. | 0 |
| 42779343 | 2026 | Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia. | 0 |
| 41231390 | 2026 | Long-term remission of CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia with myeloid sarcoma following unrelated cord blood transplantation. | 0 |
| 40390182 | 2025 | A Rare Case of Concurrent Neuroblastoma and Acute Myeloid Leukemia With CBFA2T3::GLIS2 Fusion: A Diagnostic and Therapeutic Dilemma. | 0 |
| 29427526 | 2018 | NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy. | 0 |
| 38953149 | 2024 | High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. | 0 |
| 41631723 | 2026 | Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12). | 0 |
| 39418128 | 2025 | Myeloid sarcomas with CBFA2T3 : GLIS2 fusion: clinicopathologic characterization of 4 cases mimicking small round cell tumors. | 0 |
| 42660135 | 2026 | Concurrent BCR::ABL1 and CBFA2T3::GLIS2 fusions in an adult patient with acute leukaemia. | 0 |
| 32865882 | 2021 | Utility of CD36 as a novel addition to the immunophenotypic signature of RAM-phenotype acute myeloid leukemia and study of its clinicopathological characteristics. | 0 |
| 23531517 | 2013 | NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. | 0 |
| 42934831 | 2026 | Immunophenotypic and genetic features of pediatric non-DS AMKL versus non-AMKL AML: A single-center study in China. | 0 |
| 34260140 | 2021 | Azacitidine and venetoclax for post-transplant relapse in a case of CBFA2T3/GLIS2 childhood acute myeloid leukaemia. | 0 |
| 42876107 | 2026 | [Pathogenesis and treatment advances of CBFA2T3::GLIS2 fusion gene-driven acute megakaryoblastic leukemia]. | 0 |
| 29043865 | 2018 | A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1. | 0 |
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 23153540 | 2012 | An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. | Gruber TA et al |
| 20116376 | 2010 | CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex. | Kumar R et al |
| 22391303 | 2012 | Gli-similar proteins: their mechanisms of action, physiological functions, and roles in disease. | Lichti-Kaiser K et al |
| 23045605 | 2012 | Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. | Thiollier C et al |
Summary
Fusion gene
CBFA2T3/GLIS2 CBFA2T3 (16q24.3) GLIS2 (16p13.3) M|CBFA2T3/GLIS2 CBFA2T3 (16q24.3) GLIS2 (16p13.3) M inv(16)(p13q24)
Citation
Jean-Loup Huret
inv(16)(p13q24) CBFA2T3/GLIS2
Atlas Genet Cytogenet Oncol Haematol. 2012-11-01
Online version: http://atlasgeneticsoncology.org/haematological/1624/inv(16)(p13q24)-cbfa2t3-glis2
